Penn Center for Innovation

Philly start-ups pivot and scramble, trying to survive and thrive amid pandemic

Posted on November 23, 2020 — Jessica Jones Gupta

A look at the different ways businesses are changing to adapt to COVID. The article features Pennovation tenant Tozuda: “Many other entrepreneurs had to come up with new ideas. Jessie Garcia, founder of Tozuda (www.tozuda.com), a head impact sensor for concussions, survived a succession of hard knocks. Some studies involving team sports that Garcia was…

Uniting against an invisible foe

Posted on — Jessica Jones Gupta

All across the University, researchers have launched new areas of study, reaching across disciplinary boundaries to make stunning progress in combating COVID-19. Read More on Penn Today

‘This is just the beginning’: Cell and gene therapy pioneers June and Marrazzo on industry’s past, future

Posted on November 13, 2020 — Jessica Jones Gupta

The Philadelphia Business Journal hosted a “It’s in Our Genes” event that discussed cell and gene therapies and their development in Philadelphia.  The event featured Dr. Carl June, the director of the Center for Cellular Immunotherapies at Penn’s Perelman School of Medicine. The other is Jeff Marrazzo, the co-founder and CEO of Spark Therapeutics. The article…

Gene therapy pioneer develops a new approach to curb the side effects of treatment

Posted on — Jessica Jones Gupta

Gene therapies hold huge promise for inherited diseases that attack the nervous system — but studies show they can inadvertently damage sensitive nerve cells, triggering side effects like weakness, numbness, and intense pain. Penn scientist and gene therapy pioneer James Wilson has developed, a new tactic designed to make these treatments safer for the nervous…

This Philly Scientist’s Technology Helped Make the Pfizer COVID-19 Vaccine Possible

Posted on November 12, 2020 — Jessica Jones Gupta

Drew Weissman, a professor of infectious diseases at the University of Pennsylvania whose technology the promising vaccine is based on, explains how it works. Read More in Philadelphia Magazine

This Penn scientist paved the way for the Pfizer COVID-19 vaccine

Posted on — Jessica Jones Gupta

The work of Dr. Drew Weissman of the Perelman School of Medicine and his former Penn colleague Dr Katalin Karikó form the backbone of two vaccines for COVID-19, including the one for which dramatic early results were announced this week. Read More in the Philadelphia Inquirer

Neuraly announces Strategic Sponsored Research Agreement with Penn

Posted on November 11, 2020 — Jessica Jones Gupta

Neuraly, Inc, a clinical-stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, announced a strategic sponsored research agreement with the University of Pennsylvania to study the use of NLY01 to therapeutically target a neuroinflammatory mechanism of glaucoma. Read the Press Release

Magnetic field and hydrogels could be used to grow new cartilage

Posted on October 28, 2020 — Jessica Jones Gupta

Using a magnetic field and hydrogels, a team of researchers in the Perelman School of Medicine have demonstrated a new possible way to rebuild complex body tissues, which could result in more lasting fixes to common injuries, such as cartilage degeneration. This research was published in Advanced Materials. Read More on Penn Today

Scout Bio advances novel gene therapy for the treatment of feline diabetes

Posted on — Jessica Jones Gupta

Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, announced it has initiated two pilot clinical studies to demonstrate effectiveness of an AAV expressing a GLP-1 analog (SB-009) in treating diabetic felines. Read More

Passage Bio’s PBKR03 receives Orphan Drug and Rare Pediatric Disease designations from FDA for treatment of Krabbe Disease

Posted on — Jessica Jones Gupta

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced that the FDA has granted Orphan Drug and Rare Pediatric Disease  designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). Passage Bio expects to initiate a Phase 1/2 trial for PBKR03 in…